News

Release – Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Health
0 min read



Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

News and Market Data on Onconova Therapeutics

NEWTOWN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating virtually in the H.C. Wainwright 24th Annual Global Investment Conference, which is taking place in a hybrid format at the Lotte New York Palace Hotel.

A corporate overview presented by Steven Fruchtman, M.D., President & CEO of Onconova, will be available on-demand beginning on Monday, September 12, 2022, at 7:00 a.m. ET. The presentation can be viewed here or on the “Corporate Events and
Presentations
” section of the Onconova website and will be archived for 90 days. Dr. Fruchtman and other members of the Onconova management team will also be available for virtual one-on-one meetings through the conference from September 12 – 16, 2022. Those interested in requesting a meeting should contact their H.C. Wainwright representative. 

About
Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Company
Contact:

Mark Guerin
Onconova Therapeutics, Inc.
267-759-3680

[email protected]
https://www.onconova.com/contact/

Investor
Contact:

Bruce Mackle
LifeSci Advisors, LLC
646-889-1200

[email protected]

 


Comments

0
No comments yet...
Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.